WeVote
Log In

Bill

JB

Bill

S 2918

Requires prescription drug coverage for serious mental illness without prior authorization or utilization management, including step therapy.

2026-2027 Regular Session Introduced by Jon Bramnick and 8 co-sponsors

New Jersey bill eliminates prior authorization and step therapy requirements for serious mental illness prescriptions, enabling immediate insurance coverage without approval delays.

Introduced in the Senate, Referred to Senate Commerce Committee
0
WeVote Research Nonpartisan
Bill Summary · S 2918

Legislative bill overview

S 2918 mandates that health insurance plans provide prescription drug coverage for serious mental illness medications without requiring prior authorization or utilization management techniques like step therapy. This means patients and their doctors can access these medications immediately without insurance company approval delays or requirements to try cheaper alternatives first.

Why is this important

Mental health treatment delays can have serious consequences, and prior authorization requirements often create barriers that prevent patients from accessing needed medications quickly. The bill addresses a real-world problem where insurance companies' cost-control measures can interfere with timely psychiatric care, potentially worsening outcomes for patients with serious mental illnesses.

Potential points of contention

  • Insurance cost concerns: Removing prior authorization and step therapy requirements may increase insurance premiums, as these mechanisms help control drug spending by reducing expensive brand-name medication use before generics or alternatives are tried
  • Definition ambiguity: The bill doesn't clearly define "serious mental illness," which could lead to disputes over which conditions and medications qualify, potentially creating litigation and coverage gaps
  • Market effects: Eliminating step therapy for psychiatric drugs could reduce incentives for generic drug development and may affect pharmaceutical pricing negotiations between insurers and drug manufacturers
  • Sustainability questions: Unfunded mandates on private insurers may shift costs to employers and consumers through higher premiums, or force insurers to offset costs by tightening coverage elsewhere

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.